Endonovo Therapeutics (ENDV) Non-Current Debt (2016)
Endonovo Therapeutics has reported Non-Current Debt over the past 4 years, most recently at $7355.0 for Q3 2016.
- Quarterly results put Non-Current Debt at $7355.0 for Q3 2016, up 131.07% from a year ago — trailing twelve months through Sep 2016 was $7355.0 (up 131.07% YoY), and the annual figure for FY2015 was $27654.0, changed.
- Non-Current Debt for Q3 2016 was $7355.0 at Endonovo Therapeutics, down from $10465.0 in the prior quarter.
- Over the last five years, Non-Current Debt for ENDV hit a ceiling of $119110.0 in Q1 2016 and a floor of $3183.0 in Q3 2015.
- Median Non-Current Debt over the past 4 years was $27654.0 (2015), compared with a mean of $39669.6.
- Biggest five-year swings in Non-Current Debt: decreased 17.95% in 2013 and later skyrocketed 363.95% in 2016.
- Endonovo Therapeutics' Non-Current Debt stood at $51656.0 in 2012, then decreased by 17.95% to $42386.0 in 2013, then plummeted by 34.76% to $27654.0 in 2015, then tumbled by 73.4% to $7355.0 in 2016.
- The last three reported values for Non-Current Debt were $7355.0 (Q3 2016), $10465.0 (Q2 2016), and $119110.0 (Q1 2016) per Business Quant data.